key: cord-0847432-lvhtjvtt authors: Schied, Anastasia; Trovillion, Erin; Moodley, Amaran title: SARS‐CoV‐2 infection in a neutropenic pediatric patient with leukemia: Addressing the need for universal guidelines for treatment of SARS‐CoV‐2‐positive, immunocompromised patients date: 2020-07-07 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.28546 sha: d2f2702efa076e5a2743b27efd4e4ee6a2ccdc1d doc_id: 847432 cord_uid: lvhtjvtt nan The patient is a 6-year-old female with B-lymphoblastic lymphoma in the maintenance phase of treatment, who was admitted to the hospital with fever and neutropenia per hospital standard of care. Her history was significant for symptomatic family household members who had tested positive for SARS-CoV-2. The patient had a history of 1 day of cough, but was asymptomatic on admission, remained afebrile throughout her hospitalization, and denied symptoms of cough, shortness of breath, fatigue, abdominal pain, or diarrhea. Testing was positive for SARS-CoV-2 by nasopharyngeal (NP) polymerase chain reaction (PCR). Infectious disease specialists were consulted and recommended a baseline chest X-ray (CXR) and monitoring of inflammatory markers. D-dimer, lactate dehydrogenase, and interleukin-6 were not elevated, and trended down during admission. Her ferritin was slightly elevated at 1098 ng/mL, and down-trended to 983 ng/mL on repeat testing. Her CXR was normal, and as her clinical status remained stable, imaging was not repeated prior to discharge. Her oral chemotherapy was held while neutropenic as per Children's Oncology Group AALL1131 protocol guidelines and while actively infected with the virus. The patient was discharged home after 10 days of hospitalization. She had repeat SARS-CoV-2 PCR testing of NP swab 3 weeks after her diagnosis and it was negative. Serum SARS-CoV-2 IgG testing at 6 weeks after diagnosis was positive; demonstrating that she mounted an antibody response while immunocompromised. This case report provides an example of an immunocompromised pediatric patient who had a favorable course and outcome after infection with SARS-CoV-2. She was treated with supportive care only, and did not receive any experimental antiviral therapies or intravenous immunoglobulin. In the pediatric population overall, rate of hospitalization is lower (5.7% compared to 20% in adults), and most recover within 1-2 weeks of symptom onset. 1,2 It is still unclear why younger people are not as severely affected by the virus, but theories attributing differences in immune system function prompt additional questions regarding oncology patients. 3 The literature available is limited, but our patient followed a similarly mild course to five case reports from a childhood cancer center in Lombardy, Italy. 4 Consent was provided by the patient and her family to publish information regarding her medical condition and treatment. Coronavirus disease 2019 in children -United States Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement Taking care of older patients with cancer in the context of COVID-19 pandemic Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences Elevated interleukin-6 and severe COVID-19: a meta-analysis Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state Clinical strategies for treating pediatric cancer during the outbreak of 2019 novel coronavirus infection French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2 How young patients with cancer perceive the COVID-19 (coronavirus) epidemic in Milan, Italy: is there room for other fears